Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hematologic malignancies, who are at high risk of complications after conventional myeloablative transplantation~2. Patients must have a 6/6 matched, related donor. Matching at HLA Class II will be based on PCR of sequence specific primers (SSP). Among family member transplants, serologic matching at Class I is sufficient~3. Patient age greater than 18~4. Performance status 0-2~5. Life expectancy of \> 100 days without transplantation~6. Written informed consent must be obtained in all cases from the patient~Exclusion Criteria:~1. Pregnancy~2. Prior Allogeneic Stem Cell Transplantation from any donor~3. Evidence of HIV infection or active Hepatitis B or C infection~4. Heart failure uncontrolled by medications~5. Total bilirubin \> 2.0 mg/dl that is due to hepatocellular dysfunction~6. AST \> 90~7. Cholesterol \> 300 mg/dl or Triglycerides \> 400 mg/dl while adequately treated~8. Uncontrolled bacterial, viral or fungal infection~9. Requirement for voriconazole at the time of hospital admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siro/MMF (Type: EXPERIMENTAL): Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
- Siro/MMF/Bort (Type: EXPERIMENTAL): Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) \*added with study reopening in 2012

Based on this trial design, predict the completion outcome and termination type (if applicable).